Gilead Sciences (GILD)
$68.50 0.32 (0.47%)
19:59 EDT GILD Stock Quote Delayed 30 Minutes
Previous Close $68.50
Market Cap 89.07B
PE Ratio 26.05
Volume (Avg. Vol.) 9.17M
Day's Range 68.00 - 68.82
52-Week Range 60.89 - 85.97
Dividend & Yield 2.23 (3.26%)
GILD Stock Predictions, Articles, and Gilead Sciences News
- From InvestorPlace
- From the Web
Gilead released more positive data on its Covid-19 treatment, remdesivir, laying the groundwork for bigger gains ahead for GILD stock.
Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.
GM is cutting its dividend and Apple is delaying iPhone production. Here's what happened in the stock market today.
Late last week, a Financial Times report suggested that Gilead’s coronavirus candidate drug remdesivir was not effective. However, the narrative for GILD stock requires a much broader context.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
GILD stock rose sharply in recent weeks as markets bet the company has a treatment against the novel coronavirus.
Eli Lilly, Domino's Pizza, Gilead Sciences, Las Vegas Sands and Inovio Pharmaceuticals were our top stock trades for Friday.
More than 26.3 million Americans have filed for unemployment benefits in the past five weeks. Here's the stock market today.
A report that Gilead's Covid-19 treatment, remdesivir, flopped in clinical trials is misleading, and the dip in GILD stock is an opportunity.
Coronavirus fears are roiling global markets, but these safe stocks to buy on the dip could help your portfolio weather the volatility.
Front-month oil futures plunged into negative territory in the stock market today. Here's the scoop on what's going on.
We saw equities jump to life in the stock market today, as investors hope for a cure for the coronavirus. Here's what happened on Friday.
Gilead's remdesivir appears to be an effective treatment against the coronavirus. Still, I wouldn't chase GILD stock now.
Apple launched a new iPhone, while the earnings reports continue to trickle in. Here's what happened in the stock market today.
GILD stock is rising on Gilead's potential coronavirus cure. But Gilead also has a questionable past, and it faces worrying patent disputes.
GILD stock is getting a boost from early trials of its remdesivir drug, which is showing some promise in treating the novel coronavirus.
Gilead delivered some good news on a remdesivir trial, That's positive news for GILD stock and the owners of the shares.
Lately there have been more indications that Gilead's drug will become a key treatment for the coronavirus. That's positive for GILD stock.
Clinical trial results for Gilead's remdesivir should come this month. If it's effective, GILD stock could explode higher on the news.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-batr.k/liberty-braves-group/news/should-you-be-concerned-about-the-liberty-braves-groups-nasdaqbatr-k-roe/">Read More...</a></div>
Industry Analysts Just Upgraded Their The Liberty Braves Group (NASDAQ:BATR.K) Revenue Forecasts By 37%
Celebrations may be in order for The Liberty Braves Group (NASDAQ:BATR.K) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-batr.k/liberty-braves-group/news/industry-analysts-just-upgraded-their-the-liberty-braves-group-nasdaqbatr-k-revenue-forecasts-by-37/">Read More...</a></div>
The Liberty Braves Group (NASDAQ:BATR.K) Share Price Is Down 19% So Some Shareholders Are Getting Worried
While it may not be enough for some shareholders, we think it is good to see the The Liberty Braves Group (NASDAQ:BATR.K) share price up 19% in a single quarter.<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-batr.k/liberty-braves-group/news/the-liberty-braves-group-nasdaqbatr-k-share-price-is-down-19-so-some-shareholders-are-getting-worried/">Read More...</a></div>
One thing we could say about the analysts on The Liberty Braves Group (NASDAQ:BATR.K) – they aren’t optimistic, having just made a major negative revision to their near-term (statutory) forecasts<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-batr.k/liberty-braves-group/news/these-analysts-think-the-liberty-braves-groups-nasdaqbatr-k-sales-are-under-threat/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader